The Section of Gastroenterology in the Department of Medicine at Baylor College of Medicine is recruiting men and women, 18 to 65 years of age who have been diagnosed with Crohn's disease for at least six months. This study is looking to evaluate the effectiveness and safety of investigational drug RHB-104 in patients with Crohn's disease. Volunteers must have been intolerant or had insufficient response to conventional therapy, be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Compensation provided.

For more information, see Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease (MAPUS).


Guillermina Cruz Guillermina.Cruz@bcm.eduPhone 1: (713) 798-8220
IRB: h-33083




Nov 10, 2014